Scientific advice meeting held

The planned scientific advice meeting with the Swedish Medical Products Agency was successfully held yesterday Oct 6th.

The purpose of the meeting was to present CombiGene’s treatment concept to the Agency, and to discuss the preclinical development program remaining before the first study on humans can be started as well as the preliminary design of that study. CombiGene was assisted by Munich based Granzer Regulatory Consulting & Services in preparing and conducting the meeting.

CombiGene’s CEO Jan Nilsson comments: ”The meeting with the MPA shows how far CombiGene has come now. We have a candidate drug and we now enter a new stage with our preclinical development program.  The meeting was very valuable and the CombiGene treatment concept was well received by the MPA.”

For further information:

CombiGene AB (publ)

Jan Nilsson, CEO

Tel: +46 70 4663163

Email: jan.nilsson@combigene.com

About CombiGene AB

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. Current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com .

MORE FROM THE COMPANY is a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and PRESS RELEASES are available at www.combigene.com.